<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00377962</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001AIC01</org_study_id>
    <nct_id>NCT00377962</nct_id>
  </id_info>
  <brief_title>Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation</brief_title>
  <acronym>NOCTET</acronym>
  <official_title>Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation: Results at 24 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study investigated whether initiation of everolimus together with reduction of
      calcineurin inhibitors (CNI) in maintenance heart or lung transplant patients with renal
      impairment would improve renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to Month 12</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to End of Study (Month 24)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Creatinine From Baseline to End of Study (Month 24)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Renal function was assessed by determining serum creatinine using standard laboratory methods. A positive change score indicates improved renal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Biopsy-proven Acute Rejection From Month 12 to End of Study (Month 24)</measure>
    <time_frame>Month 12 to end of study (Month 24)</time_frame>
    <description>Biopsy-proved acute rejection was defined as a treated acute rejection confirmed by biopsy, graded locally according to the International Society for Heart &amp; Lung Transplantation (ISHLT) criteria. A treated acute rejection was defined as an acute rejection clinically suspected, whether biopsy-proven or not, which had been treated and confirmed by the investigator according to the response to therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Died and Number of Patients With Graft Loss From Month 12 to End of Study (Month 24)</measure>
    <time_frame>Month 12 to end of study (Month 24)</time_frame>
    <description>Number of patients not alive and number of patients with loss of their graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Need of Dialysis From Month 12 to End of Study (Month 24)</measure>
    <time_frame>Month 12 to end of study (Month 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1) was measured by spirometry conducted according to internationally accepted standards. FEV1 is the volume delivered in the first second of a forced vital capacity (FVC) maneuver. A positive change score indicates improved lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Forced vital capacity (FVC) was measured by spirometry conducted according to internationally accepted standards. FVC is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration. A positive change score indicates improved lung function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Function (Diameter and Thickness Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), interventricular septal wall thickness (IVSTd), and posterior wall thickness (PWTd). A positive change score indicates improved left ventricular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular Function (Filling and Ejection Fraction Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were filling fraction (FF) and ejection fraction (EF). A positive change score indicates improved left ventricular function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Days of Hospitalization From Baseline to End of Study (Month 24)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Discontinued From the Study Due to Adverse Events From Month 12 to End of Study (Month 24)</measure>
    <time_frame>Month 12 to end of study (Month 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Disorder Related to Cardiac Transplantation</condition>
  <arm_group>
    <arm_group_label>Everolimus + CNI reduction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.</description>
    <arm_group_label>Everolimus + CNI reduction</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid (MPA)/azathioprine (AZA)</intervention_name>
    <description>In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Neoral®/Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin inhibitors (CNI)</intervention_name>
    <description>Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.</description>
    <arm_group_label>Everolimus + CNI reduction</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroids</intervention_name>
    <description>Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.</description>
    <arm_group_label>Everolimus + CNI reduction</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients who have undergone a heart or lung transplantation more than 12 months ago.

          -  Patients receiving Neoral® or Prograf®.

          -  Patients with a measured or calculated glomerular filtration rate (GFR) &gt; 20 and &lt; 70
             mL/min/1.73m^2. For patients with a GFR &gt; 60 and &lt; 70 mL/min/1.73m^2, a deteriorated
             renal function since the time of transplantation must be documented by at least one
             post-transplant GFR level that is &gt; 10% above the GFR level at the time of inclusion.

          -  Patients willing and capable of giving written informed consent for study
             participation and able to participate in the study for 12 months.

          -  Females of potential childbearing age must have a negative serum pregnancy test within
             7 days prior to enrollment. Effective contraception must be used during the trial and
             for 6 weeks following discontinuation of the study medication, even where there has
             been a history of infertility.

        Exclusion criteria:

          -  Patients who are recipients of multiple organ transplants.

          -  Patients with measured GFR &lt; 20 mL/min/1.73m^2 or &gt; 70 mL/min/1.73m^2.

          -  Patients with a treated acute rejection episode within the last 3 months.

          -  Patients with a platelet count of &lt; 50,000/mm^3 or with a white blood cell count of ≤
             2,500/mm^3 or with a hemoglobin value &lt; 8 g/dL.

          -  Presence of severe hypercholesterolemia (≥ 8.0 mmol/L) or hypertriglyceridemia (≥ 6.0
             mmol/L) despite conventional lipid lowering treatment.

          -  Patients currently treated or who have been treated with a mammalian target of
             rapamycin (mTOR) inhibitor.

          -  Patients who have received an investigational drug within 4 weeks.

          -  Patients who are human immunodeficiency virus positive or who have a current severe
             systemic infection requiring continued therapy according to investigator judgment.

          -  Present use of any immunosuppressive drugs other than Neoral®/Prograf®, mycophenolic
             acid/azathioprine (MPA/AZA), and/or steroids.

          -  Patients with a known hypersensitivity to drugs similar to everolimus.

          -  Symptoms of significant mental illness which, in the opinion of the investigator, may
             interfere with the patient's ability to comply with the protocol. History of drug or
             alcohol abuse within 1 year of baseline.

          -  Inability to cooperate or communicate with the investigator.

          -  Patients with any past (within the last 5 years) or present malignancy other than
             excised squamous or basal cell carcinoma.

          -  Females of childbearing potential that are planning to become pregnant, who are
             pregnant and/or lactating, or who are unwilling to use effective means of
             contraception.

          -  Patients with a planned coronary revascularization or patients who have experienced a
             major adverse cardiovascular event (MACE) within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arhus</city>
        <zip>DK-8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linkoping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2006</study_first_submitted>
  <study_first_submitted_qc>September 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2006</study_first_posted>
  <results_first_submitted>March 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2011</results_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceticals</organization>
  </responsible_party>
  <keyword>thoracic transplant recipients</keyword>
  <keyword>everolimus</keyword>
  <keyword>immunosuppressants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 12-month study in maintenance heart and lung transplant patients with a follow-up period of an additional 12 months. Results to 24 months are presented. Patients were randomized to continue their current calcineurin inhibitors (CNI) based regimen or to start everolimus with reduction of CNI blood levels.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus + CNI Reduction</title>
          <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study: 0-12 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="140"/>
                <participants group_id="P2" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Study: 12-24 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus + CNI Reduction</title>
          <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="142"/>
            <count group_id="B3" value="282"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="9.5"/>
                    <measurement group_id="B2" value="56.4" spread="10.7"/>
                    <measurement group_id="B3" value="57.8" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to Month 12</title>
        <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
        <time_frame>Baseline to Month 12</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to Month 12</title>
          <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" spread="15.1"/>
                    <measurement group_id="O2" value="48.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="15.7"/>
                    <measurement group_id="O2" value="47.5" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="10.4"/>
                    <measurement group_id="O2" value="-0.5" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to End of Study (Month 24)</title>
        <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Measured Glomerular Filtration Rate (mGFR) From Baseline to End of Study (Month 24)</title>
          <description>Renal function was assessed by determining the measured glomerular filtration rate (mGFR) using creatinine ethylenediamine tetraacetic acid (Cr-EDTA) clearance or an equivalent method. A positive change score indicates improved renal function.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.3" spread="14.7"/>
                    <measurement group_id="O2" value="49.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="16.4"/>
                    <measurement group_id="O2" value="46.8" spread="15.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="12.3"/>
                    <measurement group_id="O2" value="-2.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Creatinine From Baseline to End of Study (Month 24)</title>
        <description>Renal function was assessed by determining serum creatinine using standard laboratory methods. A positive change score indicates improved renal function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Creatinine From Baseline to End of Study (Month 24)</title>
          <description>Renal function was assessed by determining serum creatinine using standard laboratory methods. A positive change score indicates improved renal function.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="30"/>
                    <measurement group_id="O2" value="129" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="64"/>
                    <measurement group_id="O2" value="132" spread="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="53"/>
                    <measurement group_id="O2" value="3" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Biopsy-proven Acute Rejection From Month 12 to End of Study (Month 24)</title>
        <description>Biopsy-proved acute rejection was defined as a treated acute rejection confirmed by biopsy, graded locally according to the International Society for Heart &amp; Lung Transplantation (ISHLT) criteria. A treated acute rejection was defined as an acute rejection clinically suspected, whether biopsy-proven or not, which had been treated and confirmed by the investigator according to the response to therapy.</description>
        <time_frame>Month 12 to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Biopsy-proven Acute Rejection From Month 12 to End of Study (Month 24)</title>
          <description>Biopsy-proved acute rejection was defined as a treated acute rejection confirmed by biopsy, graded locally according to the International Society for Heart &amp; Lung Transplantation (ISHLT) criteria. A treated acute rejection was defined as an acute rejection clinically suspected, whether biopsy-proven or not, which had been treated and confirmed by the investigator according to the response to therapy.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Died and Number of Patients With Graft Loss From Month 12 to End of Study (Month 24)</title>
        <description>Number of patients not alive and number of patients with loss of their graft.</description>
        <time_frame>Month 12 to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Died and Number of Patients With Graft Loss From Month 12 to End of Study (Month 24)</title>
          <description>Number of patients not alive and number of patients with loss of their graft.</description>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graft Loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Need of Dialysis From Month 12 to End of Study (Month 24)</title>
        <time_frame>Month 12 to end of study (Month 24)</time_frame>
        <population>The intent-to-treat (ITT) population consisted of all patients as randomized, who were given at least one dose of study drug and had at least one post-baseline assessment. (Extension study)</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Need of Dialysis From Month 12 to End of Study (Month 24)</title>
          <population>The intent-to-treat (ITT) population consisted of all patients as randomized, who were given at least one dose of study drug and had at least one post-baseline assessment. (Extension study)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</title>
        <description>Forced expiratory volume in 1 second (FEV1) was measured by spirometry conducted according to internationally accepted standards. FEV1 is the volume delivered in the first second of a forced vital capacity (FVC) maneuver. A positive change score indicates improved lung function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Patients in the lung transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Expiratory Volume in 1 Second (FEV1) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</title>
          <description>Forced expiratory volume in 1 second (FEV1) was measured by spirometry conducted according to internationally accepted standards. FEV1 is the volume delivered in the first second of a forced vital capacity (FVC) maneuver. A positive change score indicates improved lung function.</description>
          <population>Patients in the lung transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.2"/>
                    <measurement group_id="O2" value="-0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Forced Vital Capacity (FVC) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</title>
        <description>Forced vital capacity (FVC) was measured by spirometry conducted according to internationally accepted standards. FVC is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration. A positive change score indicates improved lung function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Patients in the lung transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Forced Vital Capacity (FVC) From Baseline to End of Study (Month 24) in the Lung Transplant Subgroup</title>
          <description>Forced vital capacity (FVC) was measured by spirometry conducted according to internationally accepted standards. FVC is the volume delivered during an expiration made as forcefully and completely as possible starting from full inspiration. A positive change score indicates improved lung function.</description>
          <population>Patients in the lung transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Function (Diameter and Thickness Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</title>
        <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), interventricular septal wall thickness (IVSTd), and posterior wall thickness (PWTd). A positive change score indicates improved left ventricular function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Patients in the heart transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Function (Diameter and Thickness Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</title>
          <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD), interventricular septal wall thickness (IVSTd), and posterior wall thickness (PWTd). A positive change score indicates improved left ventricular function.</description>
          <population>Patients in the heart transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LVEDD (N = 56, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.8"/>
                    <measurement group_id="O2" value="-0.0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LVESD (N = 42, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVSTd (N = 43, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.4"/>
                    <measurement group_id="O2" value="-0.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PWTd (N = 43, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.1"/>
                    <measurement group_id="O2" value="-0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular Function (Filling and Ejection Fraction Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</title>
        <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were filling fraction (FF) and ejection fraction (EF). A positive change score indicates improved left ventricular function.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Patients in the heart transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular Function (Filling and Ejection Fraction Parameters) From Baseline to End of Study (Month 24) in the Heart Transplant Subgroup</title>
          <description>Left ventricular function was assessed by echocardiography which was performed according to local routine practice. Echocardiography parameters were filling fraction (FF) and ejection fraction (EF). A positive change score indicates improved left ventricular function.</description>
          <population>Patients in the heart transplant subgroup of the intent-to-treat (ITT) population which included all randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EF (N = 59, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="8.5"/>
                    <measurement group_id="O2" value="0.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FF (N = 42, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Days of Hospitalization From Baseline to End of Study (Month 24)</title>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Days of Hospitalization From Baseline to End of Study (Month 24)</title>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="7.4"/>
                    <measurement group_id="O2" value="16.2" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Discontinued From the Study Due to Adverse Events From Month 12 to End of Study (Month 24)</title>
        <time_frame>Month 12 to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus + CNI Reduction</title>
            <description>Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Discontinued From the Study Due to Adverse Events From Month 12 to End of Study (Month 24)</title>
          <population>Intent-to-treat (ITT) population: All randomized patients who were given at least 1 dose of study drug and had at least 1 post-baseline assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total discontinued due to AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin problems</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscular pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 months</time_frame>
      <desc>Safety population stratified by sub groups (heart patients and lung patients) and duration of core study and extension study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Control: 12 Month Heart</title>
          <description>Subgroup of &quot;Control&quot; group with heart patients at 12 months. CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E2">
          <title>Everolimus + CNI Reduction: 12 Month Heart</title>
          <description>Subgroup of &quot;everolimus + CNI reduction&quot; group with heart patients at 12 months. Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%, upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E3">
          <title>Control: 12 Month Lung</title>
          <description>Subgroup of &quot;control&quot; group with lung patients at 12 months. CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E4">
          <title>Everolimus+CNI Reduction: 12 Month Lung</title>
          <description>Subgroup of &quot;everolimus + CNI reduction&quot; group with lung patients at 12 months. Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%, upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E5">
          <title>Control: 24 Month Heart</title>
          <description>Subgroup of &quot;Control&quot; group with heart patients at 24 months. CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E6">
          <title>Everolimus + CNI Reduction: 24 Month Heart</title>
          <description>Subgroup of &quot;everolimus + CNI reduction&quot; group with heart patients at 24 months. Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%, upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E7">
          <title>Control: 24 Month Lung</title>
          <description>Subgroup of &quot;Control&quot; group with lung patients at 24 months. CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.</description>
        </group>
        <group group_id="E8">
          <title>Everolimus + CNI Reduction: 24 Month Lung</title>
          <description>Subgroup of &quot;everolimus + CNI reduction&quot; group with lung patients at 24 months. Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level &lt; 75 ng/mL or a tacrolimus trough level &lt; 4 ng/mL. MPA was reduced by 25%, upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiac failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Coronary artery atheroma haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Coronary artery disease NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oedema NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diverticulitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Food poisoning NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Inguinal hernia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pancreatitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rectal disorder NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Heart transplant rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypersensitivity NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Brain abscess NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchitis acute NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ear infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epididymitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia aspergilla</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pseudomonas aeruginosa infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyelonephritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fracture NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leg fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Biopsy lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung function decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphocyte morphology NOS abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pericardial drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malnutrition NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intervertebral disc prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localised osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Benign adrenal neoplasm NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Breast cancer female NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Carcinoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung cancer stage unspecified (exc metas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Prostate cancer NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin carcinoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness (exc vertigo)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epilepsy NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Migraine NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Restless leg syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nephropathy NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal impairment NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchostenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Excessive bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mediastinal emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Obliterative bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumothorax NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory failure (exc neonatal)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diabetic foot ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Operation NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Suture removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertension aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intracranial haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Phlebitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Postural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Venous thrombosis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Venous thrombosis deep limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="29" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leucopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermal naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Excessive bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertension aggravated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

